What’s Next in Cardiometabolic Disease Drug Development: Obesity, MASH and Beyond with MetaVia’s Hyung Heon Kim

In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Hyung Heon Kim, CEO of MetaVia, a clinical-stage biotechnology company developing treatments for cardiometabolic diseases. Mr. Kim discusses the evolving cardiometabolic disease landscape, including the connections between obesity, diabetes, liver disease and cardiovascular risk. He shares his perspective on how obesity care has changed in recent years, where unmet needs remain and how priorities such as muscle preservation, metabolic health and long-term durability are shaping the next stage of drug development. The conversation also explores MASH, a complex liver disease closely linked to metabolic dysfunction. Mr. Kim discusses why MASH remains difficult to diagnose, study and treat, and why broader treatment strategies may need to address underlying drivers such as insulin resistance, inflammation and lipid metabolism. Mr. Kim also explores the challenges of designing and conducting clinical trials in obesity and MASH. He shares his perspective on where the cardiometabolic field is headed and what biotech leaders should consider when working in fast-moving, highly competitive therapeutic areas. Tune in to learn more about the future of obesity, MASH and cardiometabolic disease treatment. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured